ERBB2 and breast cancer: Patients with HER2-positive breast cancer had a significantly longer PFS compared with luminal like or TNBC (median PFS 7.3 versus 4.5 versus 3.5 months, 95% CI 6.5-7.9 versus 4.0-5.1 versus 3.2-4.0 months, respectively; P < 0.0001; Supplementary Figure S1, available at https://doi.org/10.1016/j.esmoop.2022.100495).